Biosketch / Results /

Tatyana Feldman

Clinical Instructor, Department of Medicine

Contact Info

212/238-0100

Education

1986-1992 — Minskij Medicinskij Inst, Medical Education
1992 — Minsk State Medical School, Medical Education
1995-1998 — Beth Israel Medical Center (Medicine (Internal)), Residency Training
1998-1999 — Albert Einstein College of Medicine (Medicine (Internal)), Residency Training
1999-2002 — New York University School of Medicine (Hematology/Oncology), Clinical Fellowships

Research Interests

lymphoma vaccines

Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry
Bartlett, Nancy L; Smith, Mitchell R; Siddiqi, Tanya; Advani, Ranjana H; O'Connor, Owen A; Sharman, Jeff P; Feldman, Tatyana; Savage, Kerry J; Shustov, Andrei R; Diefenbach, Catherine S; Oki, Yasuhiro; Palanca-Wessels, Maria Corinna; Uttarwar, Mayur; Li, Martha; Yang, Jing; Jacobsen, Eric D. Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry. Leukemia & lymphoma. 2016 Nov 20;:1-10 (2314312)

Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large B-cell lymphoma
Mato, Anthony; Feldman, Tatyana; Zielonka, Tania; Singavi, Arun; Gadaletta, Gabriella; Waksmundzki, Kathryn; Bhattacharyya, Pritish; Chow, Kar Fai; Yang, Xiao; Panush, David; Agress, Harry; Rosario, Maria; Howlett, Christina; Pecora, Andrew; Goy, Andre. Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large B-cell lymphoma. Leukemia & lymphoma. 2013 May 15;54(12):2606-2612 (720222)

Final results of phase II trial of doxorubicin HCl liposome injection followed by bexarotene in advanced cutaneous T-cell lymphoma
Straus, D J; Duvic, M; Horwitz, S M; Hymes, K; Goy, A; Hernandez-Ilizaliturri, F J; Feldman, T; Wegner, B; Myskowski, P L. Final results of phase II trial of doxorubicin HCl liposome injection followed by bexarotene in advanced cutaneous T-cell lymphoma. Annals of oncology. 2013 Nov 26;25(1):206-210 (855292)

Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedside
Mato, Anthony R; Feldman, Tatyana; Goy, Andre. Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedside. Oncologist. 2012 May 7;17(5):694-707 (720252)

A phase I study evaluating ibritumomab tiuxetan (Zevalin(R)) in combination with bortezomib (Velcade(R)) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma
Beaven, Anne W; Shea, Thomas C; Moore, Dominic T; Feldman, Tatyana; Ivanova, Anastasia; Ferraro, Madlyn; Ford, Peggy; Smith, Judith; Goy, Andre. A phase I study evaluating ibritumomab tiuxetan (Zevalin(R)) in combination with bortezomib (Velcade(R)) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma. Leukemia & lymphoma. 2011 Sep 19;53(2):254-258 (720242)